What are adaptive Biotechnologies' ADPT share price targets?

6 brokerages have issued twelve-month price targets for Adaptive Biotechnologies' shares. Their ADPT share price targets range from $5.00 to $10.00. On average, they anticipate the company's stock price to reach $6.80 in the next twelve months. This suggests a possible upside of 88.4% from the stock's current price.

Is adaptive Biotechnologies a good stock to buy?

The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings. Adaptive Biotechnologies has only been the subject of 1 research reports in the past 90 days. Read more about Adaptive Biotechnologies' stock forecast and price target. CEO of Biggest AI Chipmaker Just Dropped a Bombshell…

Who owns adaptive Biotechnologies Corp (ADPT)?

Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA. View Adaptive Biotechnologies Corp. ADPT stock quote prices, financial information, real-time forecasts, and company news from CNN.